T1	HMM 60 79	efficacy and safety
T2	HMM 293 312	safety and efficacy
T3	HMM 484 518	serotonin (5-HT) receptor activity
T4	HMM 541 563	serotonin transporter.
T5	HMM 780 856	the primary efficacy end point being change from baseline at week 8 in MADRS
T6	HMM 894 903	measures.
T7	HMM 904 918	Adverse events
T8	HMM 944 1139	study, suicidal ideation and behavior were assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS), and sexual dysfunction was assessed using the Arizona Sexual Experience (ASEX) scale
T9	HMM 1313 1343	the primary efficacy end point
T10	HMM 1421 1424	mg.
T11	HMM 1425 1513	Nausea, headache, dry mouth, constipation, diarrhea, vomiting, dizziness, and flatulence
T12	HMM 1590 1611	due to adverse events
T13	HMM 1881 1955	the C-SSRS, laboratory values, electrocardiogram, or vital sign parameters
